New IQVIA Study Demonstrates Cost and Time Savings of Decentralized Trials

Rhea-AI Summary

IQVIA announced findings highlighting the benefits of decentralized clinical trials (DCT), demonstrating that they can lead to faster, cheaper, and more engaging trials compared to traditional methods.

The company provided tangible data on 14 metrics, revealing significant reductions in timelines and improved patient engagement. Notable metrics include faster timeframes from Final Protocol to First Patient In and decreased Screen Failure Rates. These insights provide valuable information for sponsors looking to optimize clinical trial designs.

Positive

• Decentralized clinical trials (DCT) offer measurable benefits, including faster timelines and cost reductions.
• Substantial improvements in patient recruitment and participation were noted with DCT models.
• The report utilized a fact-based approach with data across 14 metrics, enhancing credibility.

Negative

• None.

The study found faster, less expensive, and more engaging trials can be achieved using tech-enabled decentralized clinical trial models

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced new evidence that decentralized clinical trials (DCT) deliver measurable benefits for patients, sites and sponsors.

With one of the first fact-based examinations of the return on investment of DCTs, IQVIA offers tangible data that can help sponsors calculate the overall benefit of building clinical trials around a decentralized model. DCT models can include a range of elements such as IQVIA’s (DCT) Platform and support services, research nursing & phlebotomy solutions, direct-to-patient recruitment, risk-based monitoring, electronic clinical outcomes assessments and e-diaries that allow patients to record data remotely.

In this analysis decentralized trials were assessed against 14 metrics across three categories – productivity, quality, and trial delivery, to determine how a DCT approach compared to traditional study models. The analysis found that sponsors can achieve faster, less expensive, and more engaging trials using DCT driven protocols. Specifically, the findings show substantial reductions in timelines for Final Protocol to First Patient In (FPI), timelines for FPI to Last Patient In, Screen Failure Rate, as well as protocol deviations. The analysis highlights that, while different trials experienced varying levels of benefits from a DCT approach, making decentralized models part of a clinical research strategy from the outset can lead to significant returns.

“DCTs deliver real value for patients, sites and sponsors,” said Ronan Brown, SVP and head of Patient Centric Solutions & Decentralized Trials. “How you deploy your DCT model will determine the benefits delivered, ranging from improvements in patient recruitment and participation to higher quality data.”

Click here to read the white paper “DCTs Deliver Big ROI.” To learn more about IQVIA’s DCT platform and services, please visit iqvia.com/decentralized-trials.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005113/en/

Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com)

+1.973.316.3828

Trent Brown, IQVIA Media Relations (trent.brown@iqvia.com)

+1.919.780.3221

Source: IQVIA

FAQ

What are the benefits of decentralized clinical trials as reported by IQV?

IQVIA reported that decentralized clinical trials lead to faster, cheaper, and more engaging trials, with measurable benefits across several metrics.

Which metrics were analyzed to evaluate decentralized clinical trials?

IQVIA assessed 14 metrics related to productivity, quality, and trial delivery to evaluate decentralized clinical trials.

How does IQVIA's decentralized trial model improve patient recruitment?

The DCT model improves patient recruitment by utilizing direct-to-patient recruitment and support services, resulting in higher participation rates.

When was the IQVIA press release regarding decentralized clinical trials issued?

The press release was issued on September 7, 2022.

What stock symbol is IQVIA listed under?

IQVIA is listed under the stock symbol IQV.